• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药效学中扩展S型Emax模型的构建与验证

Formulation and Validation of an Extended Sigmoid Emax Model in Pharmacodynamics.

作者信息

Byun Jong Hyuk

机构信息

Department of Mathematics, College of Natural Sciences and Institute of Mathematical Sciences, Pusan National University, Busan, 46241, Republic of Korea.

出版信息

Pharm Res. 2024 Sep;41(9):1787-1795. doi: 10.1007/s11095-024-03752-9. Epub 2024 Aug 14.

DOI:10.1007/s11095-024-03752-9
PMID:39143408
Abstract

PURPOSE OR OBJECTIVE

Drug concentration-response curves (DRCs) are crucial in pharmacology for assessing the drug effects on biological systems. The widely used sigmoid Emax model, which accounts for response saturation, relies heavily on the effective drug concentration ( ). This reliance can lead to validation errors and inaccuracies in model fitting. The Emax model cannot generate multiple DRCs, raising concerns about whether the dataset is fully utilized.

METHODS

This study formulates an extended Emax (eEmax) model designed to overcome these limitations. The eEmax model generates multiple DRCs from a single dataset by using various estimated , while keeping fixed, rather than estimating an value as in the Emax model.

RESULTS

This model effectively captures a broader range of concentration-response behavior, including non-sigmoidal patterns, thus providing greater flexibility and accuracy compared to the Emax model. Validation using various drug-response data and PKPD frameworks demonstrates the eEmax model's improved accuracy and versatility in handling concentration-response data.

CONCLUSIONS

The eEmax model provides a robust and flexible method for drug concentration-response analysis, facilitating the generation of multiple DRCs from a single dataset and reducing the possibility of validation errors. This model is particularly valuable for its ease of use and its capability to fully utilize datasets, providing its potential in PKPD modeling and drug discovery.

摘要

目的或目标

药物浓度-反应曲线(DRCs)在药理学中对于评估药物对生物系统的作用至关重要。广泛使用的S形Emax模型考虑了反应饱和情况,但严重依赖有效药物浓度( )。这种依赖可能导致模型拟合中的验证错误和不准确。Emax模型无法生成多个DRCs,引发了对数据集是否得到充分利用的担忧。

方法

本研究制定了一个扩展的Emax(eEmax)模型,旨在克服这些局限性。eEmax模型通过使用各种估计的 ,在保持 固定的情况下,从单个数据集中生成多个DRCs,而不是像Emax模型那样估计一个 值。

结果

该模型有效地捕捉了更广泛的浓度-反应行为,包括非S形模式,因此与Emax模型相比具有更大的灵活性和准确性。使用各种药物反应数据和PKPD框架进行验证,证明了eEmax模型在处理浓度-反应数据方面提高了准确性和通用性。

结论

eEmax模型为药物浓度-反应分析提供了一种强大而灵活的方法,有助于从单个数据集中生成多个DRCs,并减少验证错误的可能性。该模型因其易用性和充分利用数据集的能力而特别有价值,在PKPD建模和药物发现中具有潜力。

相似文献

1
Formulation and Validation of an Extended Sigmoid Emax Model in Pharmacodynamics.药效学中扩展S型Emax模型的构建与验证
Pharm Res. 2024 Sep;41(9):1787-1795. doi: 10.1007/s11095-024-03752-9. Epub 2024 Aug 14.
2
Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.群体药效学:浓度和效应控制临床试验策略
Ann Pharmacother. 1996 Jan;30(1):12-9. doi: 10.1177/106002809603000102.
3
Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.在存在可能的非单调性的情况下,类风湿关节炎 2a 期概念验证研究的设计考虑因素和分析计划。
BMC Med Res Methodol. 2017 Oct 2;17(1):149. doi: 10.1186/s12874-017-0416-3.
4
Population Pharmacodynamic Modeling Using the Sigmoid E Model: Influence of Inter-individual Variability on the Steepness of the Concentration-Effect Relationship. a Simulation Study.应用 Sigmoid E 模型的群体药效动力学建模:个体间变异性对浓度-效应关系陡峭度的影响。一项模拟研究。
AAPS J. 2020 Dec 24;23(1):10. doi: 10.1208/s12248-020-00549-7.
5
The efficiency concept in pharmacodynamics.药效学中的效能概念。
Clin Pharmacokinet. 1999 May;36(5):375-89. doi: 10.2165/00003088-199936050-00005.
6
Construction of antagonist dose-response curves for estimation of pA2-values by Schild-plot analysis and detection of allosteric interactions.构建拮抗剂剂量反应曲线,用于通过Schild图分析估计pA2值并检测变构相互作用。
Br J Pharmacol. 1992 Jul;106(3):710-6. doi: 10.1111/j.1476-5381.1992.tb14399.x.
7
Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development.系统药理学:在药物发现和开发中连接系统生物学和药代动力学-药效学(PKPD)。
Pharm Res. 2011 Jul;28(7):1460-4. doi: 10.1007/s11095-011-0467-9. Epub 2011 May 11.
8
Temporal linear mode complexity as a surrogate measure of the anesthetic drug effects during sevoflurane anesthesia.时间线性模式复杂度作为七氟醚麻醉期间麻醉药物效应的替代测量指标。
Korean J Anesthesiol. 2013 Nov;65(5):385-96. doi: 10.4097/kjae.2013.65.5.385. Epub 2013 Nov 29.
9
gPKPDSim: a SimBiology-based GUI application for PKPD modeling in drug development.gPKPDSim:一个基于 SimBiology 的 GUI 应用程序,用于药物开发中的 PKPD 建模。
J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):259-275. doi: 10.1007/s10928-017-9562-9. Epub 2018 Jan 4.
10
Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.苯妥英对大鼠抗惊厥及脑电图作用的药代动力学-药效学建模
J Pharmacol Exp Ther. 1998 Feb;284(2):460-6.

本文引用的文献

1
Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations.靶向药物处置模型的近似有效性条件:一种新的一阶近似及其与其他近似的比较。
PLoS Comput Biol. 2024 Apr 24;20(4):e1012066. doi: 10.1371/journal.pcbi.1012066. eCollection 2024 Apr.
2
Extended transit compartment model to describe tumor delay using Coxian distribution.采用 Coxian 分布描述肿瘤时滞的扩展转运室模型。
Sci Rep. 2022 Jun 16;12(1):10086. doi: 10.1038/s41598-022-13836-4.
3
Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges.
药代动力学-药效学模型在药物递送中的应用:发展与挑战
Front Pharmacol. 2020 Jul 3;11:997. doi: 10.3389/fphar.2020.00997. eCollection 2020.
4
Parameter estimation for sigmoid E models in exposure-response relationship.暴露-反应关系中S形E模型的参数估计
Transl Clin Pharmacol. 2017 Jun;25(2):74-84. doi: 10.12793/tcp.2017.25.2.74. Epub 2017 Jun 15.
5
Pharmacodynamic principles and the time course of delayed and cumulative drug effects.药效学原理以及延迟和累积药物效应的时间进程。
Transl Clin Pharmacol. 2018 Jun;26(2):56-59. doi: 10.12793/tcp.2018.26.2.56. Epub 2018 Jun 18.
6
Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials.外照射放疗后前列腺癌的剂量反应和分割敏感性:随机试验的荟萃分析。
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):858-865. doi: 10.1016/j.ijrobp.2017.12.011. Epub 2017 Dec 15.
7
Delayed logistic indirect response models: realization of oscillating behavior.延迟逻辑间接响应模型:振荡行为的实现。
J Pharmacokinet Pharmacodyn. 2018 Feb;45(1):49-58. doi: 10.1007/s10928-017-9563-8. Epub 2018 Jan 8.
8
The dose-response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis.根治性前列腺切除术后挽救性放疗的剂量反应:系统评价和荟萃分析。
Radiother Oncol. 2016 Nov;121(2):199-203. doi: 10.1016/j.radonc.2016.10.026. Epub 2016 Nov 15.
9
Intracellular PK/PD Relationships of Free and Liposomal Doxorubicin: Quantitative Analyses and PK/PD Modeling.游离和脂质体阿霉素的细胞内药代动力学/药效学关系:定量分析与药代动力学/药效学建模
Mol Pharm. 2016 Apr 4;13(4):1358-65. doi: 10.1021/acs.molpharmaceut.6b00008. Epub 2016 Mar 16.
10
In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis.头孢喹肟对副猪嗜血杆菌的体外动态药代动力学/药效学(PK/PD)建模及PK/PD界值
BMC Vet Res. 2015 Feb 13;11:33. doi: 10.1186/s12917-015-0343-7.